Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-573.70% · OPTIONAL · NOT_ENOUGH_HISTORY
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
AUPH · Jun 30, 2021
Aurinia Pharmaceuticals Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001628280-21-015863General Corporate
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
262.48% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.gross_margin
95.35% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.operating_margin
-711.99% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
152.43% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
117.11% · OPTIONAL · NOT_ENOUGH_HISTORY
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History12 statesSelf-history eligible
Mar 31, 20210/6 normalizedLevel 3Jun 30, 20210/6 normalizedLevel 3Sep 30, 20210/6 normalizedLevel 3Dec 31, 20210/7 normalizedLevel 3Mar 31, 20220/7 normalizedLevel 3Jun 30, 20220/7 normalizedLevel 3Sep 30, 20220/7 normalizedLevel 3Dec 31, 20225/7 normalizedLevel 3Mar 31, 20236/7 normalizedLevel 3Jun 30, 20236/7 normalizedLevel 3Sep 30, 20236/7 normalizedLevel 3Sep 30, 20267/7 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- -5857.88%
- Current
- -573.70%
- Delta
- 5284.18%
- Previous
- 1743.54%
- Current
- 262.48%
- Delta
- -1481.07%
- Previous
- 94.75%
- Current
- 95.35%
- Delta
- 0.60%
- Previous
- -5529.87%
- Current
- -711.99%
- Delta
- 4817.87%
- Previous
- 1075.82%
- Current
- 152.43%
- Delta
- -923.39%
- Previous
- 855.69%
- Current
- 117.11%
- Delta
- -738.57%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · AUPH Fundamental State →Has State · Aurinia Pharmaceuticals Inc. →Transitioned To · AUPH Fundamental State →Transitioned To · AUPH CASH_GENERATION_INCREASED →Transitioned To · AUPH INVENTORY_PRESSURE_DECREASED →Transitioned To · AUPH MARGIN_INCREASED →Transitioned To · AUPH PROFITABILITY_INCREASED →Transitioned To · AUPH R_AND_D_INTENSITY_DECREASED →Transitioned To · AUPH SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.